Adagio Therapeutics

$6.18 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Adagio Therapeutics

Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19). The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.

Stock Analysis

last close $6.29
1-mo return -38.9%
3-mo return -81.3%
avg daily vol. 4.73M
52-week high 78.82
52-week low 4.92
market cap. $700M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $--
inst own. 65.4%
baraka

Subscribe now for daily local and international financial news

Subscribe